170726-04-2

Basic information

• Product Name: 4-{4-[5-(2-Carboxy-ethyl)-4,5-dihydro-isoxazol-3-yl]-phenoxymethyl}-piperidine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-{4-[5-(2-Carboxy-ethyl)-4,5-dihydro-isoxazol-3-yl]-phenoxymethyl}-piperidine-1-carboxylic acid tert-butyl ester
• CAS NO: 170726-04-2
• Molecular Weight: 432.517
• Mol File: 170726-04-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-{4-[5-(2-Carboxy-ethyl)-4,5-dihydro-isoxazol-3-yl]-phenoxymethyl}-piperidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-{4-[5-(2-Carboxy-ethyl)-4,5-dihydro-isoxazol-3-yl]-phenoxymethyl}-piperidine-1-carboxylic acid tert-butyl ester(170726-04-2)
• EPA Substance Registry System: 4-{4-[5-(2-Carboxy-ethyl)-4,5-dihydro-isoxazol-3-yl]-phenoxymethyl}-piperidine-1-carboxylic acid tert-butyl ester(170726-04-2)

Safety Data

• Hazardous Substances Data: 170726-04-2(Hazardous Substances Data)

Upstream product

• 217965-30-5 C₁₈H₂₅ClN₂O₄ 
• 818-57-5 Methyl 4-pentenoate 
• 170726-03-1 4-{4-[5-(2-Methoxycarbonyl-ethyl)-4,5-dihydro-isoxazol-3-yl]-phenoxymethyl}-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Discovery of potent isoxazoline glycoprotein IIb/IIIa receptor antagonists

Using the isoxazoline as a common structural feature, three series of glycoprotein IIb/IIIa receptor antagonists were evaluated, culminating in the discovery of XR299 (30). In an in vitro assay of platelet inhibition, XR299 had an IC50 of 0.24 μM and was a potent antiplatelet agent when dosed intravenously in a canine model. It was shown through X-ray studies of the cinchonidine salt 49 that the receptor required the 5(R)-stereochemistry for high potency. The ethyl ester prodrug of XR299, XR300 (29), was orally active in the dog.